NCT06308523View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 18, 2024

Primary Completion Date

May 13, 2024

Study Completion Date

May 13, 2024

Conditions
Healthy Subjects
Interventions
DRUG

AP303 150 μg

AP303 Tablet 150 μg QD

DRUG

Placebo 150 μg

Placebo Tablet 150 μg QD

DRUG

AP303 300 μg

AP303 Tablet 300 μg QD

DRUG

Placebo 300 μg

Placebo Tablet 300 μg QD

Trial Locations (1)

Unknown

Peking University Third Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Alebund Pharmaceuticals

INDUSTRY

NCT06308523 - A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter